Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
G-quadruplex (G4) DNA structures at G4–duplex junctions are specialized nucleic acid motifs formed in guanine-rich sequences where a four-stranded quadruplex transitions into a standard double-stranded helix (Nature Communications, 2021). These junctions are prevalent in regulatory regions of the genome, particularly within the promoters of oncogenes like c-MYC and at telomeric ends, where they serve as critical checkpoints for transcription and chromosomal stability (Nucleic Acids Research, 2020). In oncology, these structures are targeted because their stabilization can selectively downregulate the expression of genes driving tumor growth or trigger catastrophic DNA damage in cancer cells (Trends in Cancer, 2017). Small molecules such as Pidnarulex are designed to bind and stabilize these junctions, effectively halting the progression of the replication or transcription machinery (Journal of Clinical Oncology, 2019). The unique geometry of the junction provides a more specific binding pocket compared to the G-tetrad alone, potentially allowing for improved drug selectivity (Nature Chemistry, 2017). Beyond cancer, G4 structures are implicated in viral genome regulation and the pathogenesis of neurodegenerative diseases associated with nucleotide repeat expansions (Frontiers in Genetics, 2020). Despite their therapeutic potential, the widespread occurrence of G-rich sequences throughout the human genome poses significant challenges for achieving the high selectivity required to avoid disrupting normal cellular functions (Nature Reviews Drug Discovery, 2011).
Stabilization of G-quadruplex structures at junctions to inhibit oncogene transcription, block telomerase elongation, induce DNA replication stress, and trigger DNA damage responses in malignant cells.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on G-quadruplex DNA structure at G4–duplex junction (G4-duplex junction).